

## Yale Public Health Professor Suggests 60% of New COVID-19 Patients Have Received Vaccine

'Clinicians have been telling me that more than half of the new COVID cases that they're treating are people who have been vaccinated,' said Dr. Harvey Risch.

By Dorothy Cummings McLean Global Research, April 22, 2021 LifeSiteNews 21 April 2021 Region: <u>USA</u> Theme: <u>Science and Medicine</u>

All Global Research articles **can be read in 51 languages by activating the "Translate Website"** drop down menu on the top banner of our home page (Desktop version).

\*\*\*

An American Professor of Epidemiology at Yale University revealed that the majority of people now coming down with COVID-19 have been vaccinated against the virus.

"Clinicians have been telling me that more than half of the new COVID cases that they're treating are people who have been vaccinated," said Dr. Harvey Risch.

A professor at the Yale School of Public Health, Risch appeared on Steve Bannon's "War Room" program and contrasted the public's perception of the vaccines' efficacy with that of the medical establishment.



"I think the American public has been sold on the vaccine by the research that shows that they reduce the infection of mild to moderate symptomatic infection by somewhere between 60-90% depending upon age and vaccine and so on and that is pretty good performance for an individual who wants to take a vaccine to protect himself," Risch said.

"However, that is not the measure that public health infrastructure, administration, and Dr. Fauci are using to look at the efficacy of the vaccine."

What the medical establishment is most interested in, Risch believes, is whether or not the vaccines prevent the spread of the infection. As Big Pharma has not provided this information, Risch recommends looking at the data from places where the vaccine has been used.

"For that the best place so far has been the mass rollout in Israel where the Pfizer vaccine was given to more than half the population now," the epidemiologist said.

"And in Israel, the studies there show that it reduces the spread of the infection by somewhere around 50-60% so that contributes to herd immunity," he continued.

"But it is not an overnight shutting down of the spread. It is a slow and continuing benefit for society to do that. But it is totally different than each individual's protection of, say, 90%."

This should be a wake-up call to people who think the vaccine will "free them up from all restrictions," he said. This cannot happen because, although they might not get symptoms, the vaccine cuts the actual transmission of the virus only by a half. Risch said clinicians have told him that over half of new coronavirus cases have already had a vaccine.

"They've estimated that more than 60% of the new cases that they are treating - COVID cases - have been people who have been vaccinated," Risch said.

Last summer Dr. Risch caused a stir in medical circles, <u>including his own workplace</u>, when he advocated the <u>use of hydroxychloroquine</u> as a treatment for the coronavirus. On May 27, he published an article in the American Journal of Epidemiology entitled "Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis." In August, he told Fox News host Mark Levin that the evidence was <u>"overwhelming"</u> that hydroxychloroquine reduces risk of hospitalization or death from COVID-19.

\*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

## **Comment on Global Research Articles on our Facebook page**

## **Become a Member of Global Research**

Articles by: Dorothy Cummings McLean

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: <a href="mailto:publications@globalresearch.ca">publications@globalresearch.ca</a>

<u>www.globalresearch.ca</u> contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca